Blog

Subcutaneous Artery Assays Help Us to Understand Blood Pressure Regulation
Explore how subcutaneous artery assays enhance understanding of blood pressure regulation and aid in the development of safer, more effective cardiovascular drugs.
07 July 2025

Able Biott Single-use Bioreactors Enhance the Development of Disease Models and Cell Therapy
Discover how Able Biott single-use bioreactors enhance disease modeling and cell therapy development through scalable, efficient iPSC culture solutions.
03 July 2025

Why mRNA Reprogramming Is the Key to Safer and Faster iPSC Generation?
Discover how mRNA reprogramming enhances the safety, efficiency, and scalability of iPSC generation for therapeutic applications. Explore REPROCELL's innovative technologies and services.
10 June 2025

New Therapeutic Targets: The Role of IL17-Related Genes in Precision Medicine
Discover how IL-17 related genes could revolutionize psoriasis treatment, offering new therapeutic targets and paving the way for precision medicine advancements.
09 June 2025
Upcoming Events
Conferences we will be attending, and webinars hosted by us
Come meet us on 4 September 2025 / Maryland, USA. Venue: Bethesda North Marriott Hotel & Conference Center
Come meet us on 6-8 October (in person) & 9-10 October (virtual) at Phoenix, AZ, USA. Venue: Arizona Biltmore
Come meet us 20-21 October 2025 / ACC Liverpool Exhibition Centre, UK / Booth #B07
Corporate News
REPROCELL Announces U.S. FDA Drug Master File Submittal for StemRNA™ Clinical iPSC Seed Clones
REPROCELL is pleased to announce the successful submittal of its StemRNA™ Clinical iPSC Seed Clones with the U.S. Food and Drug Administration (FDA) via a Type II Drug Master File (DMF).
22 July 2025
Scottish Health Minister Visits REPROCELL Japan to Strengthen Life Sciences Collaboration
Scottish Health Minister Neil Gray visits REPROCELL Japan to enhance life sciences collaboration, highlighting strong ties and innovative healthcare advancements between Scotland and Japan.
02 July 2025
REPROCELL Launches Immune Modulated iPSC Products
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
05 May 2025